Unknown

Dataset Information

0

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.


ABSTRACT: Flavopiridol is a small molecule inhibitor of cyclin-dependent kinases (CDK) known to impair global transcription via inactivation of positive transcription elongation factor b. It has been demonstrated to have significant activity predominantly in chronic lymphocytic leukemia and acute myeloid leukemia in phase I/II clinical trials while other similar CDK inhibitors are vigorously being pursued in pre-clinical and clinical studies. Although flavopiridol is a potent therapeutic agent against blood diseases, some patients still have primary or acquired resistance throughout their clinical course. Considering the limited knowledge of resistance mechanisms of flavopiridol, we investigated the potential mechanisms of resistance to flavopiridol in a cell line system, which gradually acquired resistance to flavopiridol in vitro, and then confirmed the mechanism in patient samples. Herein, we present that this resistant cell line developed resistance through up-regulation of phosphorylation of RNA polymerase II C-terminal domain, activation of CDK9 kinase activity, and prolonged Mcl-1 stability to counter flavopiridol's drug actions. Further analyses suggest MAPK/ERK activation-mediated Mcl-1 stabilization contributes to the resistance and knockdown of Mcl-1 in part restores sensitivity to flavopiridol-induced cytotoxicity. Altogether, these findings demonstrate that CDK9 is the most relevant target of flavopiridol and provide avenues to improve the therapeutic strategies in blood malignancies.

SUBMITTER: Yeh YY 

PROVIDER: S-EPMC4413609 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.

Yeh Yuh-Ying YY   Chen Rong R   Hessler Joshua J   Mahoney Emilia E   Lehman Amy M AM   Heerema Nyla A NA   Grever Michael R MR   Plunkett William W   Byrd John C JC   Johnson Amy J AJ  

Oncotarget 20150201 5


Flavopiridol is a small molecule inhibitor of cyclin-dependent kinases (CDK) known to impair global transcription via inactivation of positive transcription elongation factor b. It has been demonstrated to have significant activity predominantly in chronic lymphocytic leukemia and acute myeloid leukemia in phase I/II clinical trials while other similar CDK inhibitors are vigorously being pursued in pre-clinical and clinical studies. Although flavopiridol is a potent therapeutic agent against blo  ...[more]

Similar Datasets

| S-EPMC6920180 | biostudies-literature
| S-EPMC5824552 | biostudies-literature
| S-EPMC3382371 | biostudies-literature
| S-EPMC8136118 | biostudies-literature
| S-EPMC7248782 | biostudies-literature
2014-07-22 | E-MEXP-3978 | biostudies-arrayexpress
| S-EPMC6355967 | biostudies-literature
| S-EPMC3173732 | biostudies-literature
| S-EPMC8773807 | biostudies-literature
| S-EPMC4613943 | biostudies-literature